Grant: Idea to Innovation
McMaster University
$125,000.00
IFlowPlate - a universal platform for vascularizing organoids
EF 2021-22
Résumé
To improve the precision of drug discovery at the preclinical stage, there is a growing demand for advanced human-based tissue models that complement the use of animals and cell-based assays. In recent years, organoids have emerged as a promising alternative. Organoids derived from stem cells can recapitulate the developmental process and model the biological complexity of an organ. However, most organoid models lack perfusable blood vessel networks which are the most prevalent biological structures that control a wide range of organ functions. To solve this problem, we developed a platform technology (IFlowPlate) that can grow an array of perfusable blood vessel networks to vascularize organoids on demand. Using the platform, we demonstrated that colon organoids and liver spheroids can be vascularized to model complex biological processes, such as intravascular drug and immune cell delivery and inflammatory response. From our initial market assessment, we received overwhelming interest in the technology and have formed multiple collaborations with major pharmaceutical companies and life science reagent distributors. However, there are still a number of engineering design-related questions that we can address to better align our technology with the needs of the end-users. In this proposed research, we seek (AIM 1) to establish uni-directional vascular flow in IFlowPlate, (AIM 2) to access the lumen of organoids for barrier function assays, and (AIM 3) to convert the IFlowPlate from the current 384-well plate format to a 96- or 24- well plate format for academic users. This work will resolve the key concerns from the end-users, significantly expand the application, and better prepare the platform technology for industry adoption. The team has a track record of developing and commercializing innovative tissue culture platforms and plans to commercialize IFlowPlate through a biotech startup company. We have initiated collaboration with multiple pharmaceutic companies and CROs to test our technology and attracted early investments from a venture capital firm.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
566853-2021
Name nom
Zhang, Boyang
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1
Partie
1
Nb partie
1
Application title
IFlowPlate - a universal platform for vascularizing organoids
Keyword
NSERC
Application summary
To improve the precision of drug discovery at the preclinical stage, there is a growing demand for advanced human-based tissue models that complement the use of animals and cell-based assays. In recent years, organoids have emerged as a promising alternative. Organoids derived from stem cells can recapitulate the developmental process and model the biological complexity of an organ. However, most organoid models lack perfusable blood vessel networks which are the most prevalent biological structures that control a wide range of organ functions. To solve this problem, we developed a platform technology (IFlowPlate) that can grow an array of perfusable blood vessel networks to vascularize organoids on demand. Using the platform, we demonstrated that colon organoids and liver spheroids can be vascularized to model complex biological processes, such as intravascular drug and immune cell delivery and inflammatory response. From our initial market assessment, we received overwhelming interest in the technology and have formed multiple collaborations with major pharmaceutical companies and life science reagent distributors. However, there are still a number of engineering design-related questions that we can address to better align our technology with the needs of the end-users. In this proposed research, we seek (AIM 1) to establish uni-directional vascular flow in IFlowPlate, (AIM 2) to access the lumen of organoids for barrier function assays, and (AIM 3) to convert the IFlowPlate from the current 384-well plate format to a 96- or 24- well plate format for academic users. This work will resolve the key concerns from the end-users, significantly expand the application, and better prepare the platform technology for industry adoption. The team has a track record of developing and commercializing innovative tissue culture platforms and plans to commercialize IFlowPlate through a biotech startup company. We have initiated collaboration with multiple pharmaceutic companies and CROs to test our technology and attracted early investments from a venture capital firm.